Between the US government shutdown, crippling international tariffs, debilitating funding cuts to critical research, and the general policy whiplash in Washington DC, it's little wonder many US-based ...

The European Medicines Agency’s EMA’s human medicines committee (CHMP) recommended seven novel medicines for approval at its November 2025 meeting.

The race to find a new treatment for hair loss hotted up last month with two mega funding rounds for Pelage Pharmaceuticals and Veradermics. The deals also demonstrated biopharma’s growing interest in ...

US pharma major Bristol Myers Squibb—in collaboration with Johnson & Johnson—has announced the decision to stop the Phase III Librexia ACS trial evaluating the efficacy and safety of milvexian when ...

TandemAI has announced that it has secured a $22 million Series A extension to further develop its drug discovery platform, which combines advanced AI, physics-based computational methods, and wet lab ...

Chinese biotech Biokin Pharmaceutical (SHA: 688506) has postponed its planned Hong Kong share listing, citing “prevailing market conditions” as analysts point to cooling risk appetite late in the year ...

Ireland-based Avadel Pharmaceuticals today announced that it has received an unsolicited proposal from Denmark’s Lundbeck to acquire Avadel, whose shares shot up 21.7% to $19.24 in pre-market activity ...

US medtech firm Terumo Blood and Cell Technologies has appointed Liza Loidolt as general manager of its cell and gene therapy business, marking a sharper strategic push into advanced therapeutics.

Merck & Co has struck a $9.2 billion deal to acquire biotechnology company Cidara Therapeutics in a move that bolsters the US pharma giant’s respiratory portfolio and pipeline as it braces for the ...

Neurvati Neurosciences, the neuroscience development platform of Blackstone Life Sciences, has announced the appointment of Carlos Martin as chief commercial officer (CCO).

UK-based life sciences venture capital firm Medicxi today announced the closing of Medicxi V, a 500 million-euros ($579.5 million) fund dedicated to building and backing innovative European ...

Gate Bioscience has raised $65 million in an oversubscribed series B to advance its first molecular gate candidates, a novel class of oral small molecules designed to eliminate disease-driving ...